Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Opsonix Inc.
DescriptionRecombinant protein derived from human opsonin mannose binding lectin (MBL) fused to the Fc region of human immunoglobulin
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentDiscovery
Standard IndicationSepsis
Indication DetailsTreat sepsis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today